Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Symbicort Turbuhaler forteDrug: Charcoal and Symbicort TurbuhalerDrug: Charcoal and Budesonide/formoterol Easyhaler 320/9 microgDrug: Budesonide/formoterol Easyhaler 320/9 microg
- Registration Number
- NCT01593826
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Brief Summary
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- Healthy males and females aged 18-60 years.
- Normal weight, at least 50 kg.
Read More
Exclusion Criteria
- Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease.
- Any clinically significant abnormal laboratory value or physical finding that may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
- Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study.
- Known hypersensitivity to the active substance(s) or the excipient of the drug.
- Pregnant or lactating females.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Symbicort Turbuhaler Symbicort Turbuhaler forte - Charcoal and Symbicort Turbuhaler Charcoal and Symbicort Turbuhaler - Charcoal and Budesonide/formoterol Easyhaler Charcoal and Budesonide/formoterol Easyhaler 320/9 microg - Budesonide/formoterol Easyhaler Budesonide/formoterol Easyhaler 320/9 microg -
- Primary Outcome Measures
Name Time Method Pharmacokinetic parameter Cmax of plasma budesonide concentration within 12 h Pharmacokinetic parameter Cmax of plasma formoterol concentration within 24 h Pharmacokinetic parameter AUCt of plasma budesonide concentration Within 12 h Pharmacokinetic parameter AUCt of plasma formoterol concentration Within 24 h
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Orion Pharma Clinical Pharmacology Unit
🇫🇮Espoo, Finland